**Appendix Table E46. Baseline characteristics of a mixed patient population with ischemic heart, cerebrovascular and peripheral vascular disease in studies assessing the predictive ability of VASP**

| **Author, year [ref]****UID****Country****Study Name** | **Demographics****Total N Enrolled** **Race (% by group)****Male (%)****Age\*** | **Vascular disease history****Previous CAD (%)****Previous heart failure(%)****Previous TIA/stroke(%)****History of PCI or CABG(%):****Stable angina(%)****Unstable angina(%)****Previous PAD(%)****History of MI(%)****STEMI/non-STEMI(%)** | **Vascular risk factors****Dyslipidemia (%)****Smokers (%)****BP(mmHg diastolic/systolic** **HTN (%)****Diabetes (%)** | **Prior medications****(pre-study)****Vitamin K antagonist(%)****Clopidogrel(%)****Aspirin(%)****PPI(%)** | **Procedural data****Stent implantation(%)****Type of stent(%)****Multi-or single vessel(%)**  | **Current indication for clopidogrel treatment** | **Current antiplatelet regimen** | **Co-medication** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reny, 201222615340France and SwitzerlandADRIE | 771NR8162.9 | 66NR13NRNRNR21NRNR | 3675NR5722 | NR9985.529 | NRNRNR | patients with symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovasculardisease, and/or peripheral artery disease) | non–enteric-coated aspirin and/or clopidogrel | NR |

\*Mean (standard deviation), unless otherwise stated